announced an exclusive deal with Memorial Sloan Kettering Cancer Center (MSK). The partnership gives access to MSK’s computational pathology intellectual property and its 25 million pathology slides — one of the largest repositories of de-identified pathology data in the world, which will use to feed its AI service. The startup also announced that it raised $25 million in funding, led by Breyer Capital, whose CEO sits on the board., a healthcare startup that applies artificial intelligence (AI) to cancer pathology, has come out of stealth mode and
and MSK hope that AI can help speed up the process of diagnosing some cancers, freeing up doctors’ time. Pathologists review dozens of slides to determine whether a patient has cancer, with only a few of these slides being relevant to the diagnosis. The company aims to have its AI do an initial review of the slides so doctors only need to review relevant slides to make a diagnosis. For now, MSK is only customer, but the company plans to expand its base over time.
The New York-based company plans to continue to develop computational programs across diagnostic pathology. It will start by focusing on clinical applications in breast cancer, prostate cancer, and other common cancers.
joins a slew of tech companies and research labs that are using their AI expertise to augment the treatment and diagnosis of cancer such as Microsoft, John Hopkins University and PathAI